235 related articles for article (PubMed ID: 31882334)
1. Effect of CXCL12 and Its Receptors on Unpredictable Renal Cell Carcinoma.
Floranović MP; Veličković LJ
Clin Genitourin Cancer; 2020 Aug; 18(4):e337-e342. PubMed ID: 31882334
[TBL] [Abstract][Full Text] [Related]
2. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
3. Expression and prognostic value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell carcinoma.
Potić Floranović M; Ristić Petrović A; Veličković F; Janković Veličković L
Clin Exp Nephrol; 2021 Oct; 25(10):1057-1069. PubMed ID: 34109508
[TBL] [Abstract][Full Text] [Related]
4. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
Nazari A; Khorramdelazad H; Hassanshahi G
Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
[TBL] [Abstract][Full Text] [Related]
5. Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients.
Katsura M; Shoji F; Okamoto T; Shimamatsu S; Hirai F; Toyokawa G; Morodomi Y; Tagawa T; Oda Y; Maehara Y
Cancer Sci; 2018 Jan; 109(1):154-165. PubMed ID: 29032612
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells.
Ieranò C; Santagata S; Napolitano M; Guardia F; Grimaldi A; Antignani E; Botti G; Consales C; Riccio A; Nanayakkara M; Barone MV; Caraglia M; Scala S
Cell Death Dis; 2014 Jul; 5(7):e1310. PubMed ID: 24991762
[TBL] [Abstract][Full Text] [Related]
7. High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma.
Wang L; Chen W; Gao L; Yang Q; Liu B; Wu Z; Wang Y; Sun Y
World J Surg Oncol; 2012 Oct; 10():212. PubMed ID: 23039915
[TBL] [Abstract][Full Text] [Related]
8. Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis.
Gahan JC; Gosalbez M; Yates T; Young EE; Escudero DO; Chi A; Garcia-Roig M; Satyanarayana R; Soloway MS; Bird VG; Lokeshwar VB
J Urol; 2012 Mar; 187(3):827-33. PubMed ID: 22245330
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
10. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis.
Pan J; Mestas J; Burdick MD; Phillips RJ; Thomas GV; Reckamp K; Belperio JA; Strieter RM
Mol Cancer; 2006 Nov; 5():56. PubMed ID: 17083723
[TBL] [Abstract][Full Text] [Related]
11. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
12. The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies.
Mehrpouri M
Eur J Pharmacol; 2022 Apr; 920():174831. PubMed ID: 35183534
[TBL] [Abstract][Full Text] [Related]
13. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy.
Mousavi A
Immunol Lett; 2020 Jan; 217():91-115. PubMed ID: 31747563
[TBL] [Abstract][Full Text] [Related]
14. CXCL12 (SDF-1)/CXCR4 pathway in cancer.
Teicher BA; Fricker SP
Clin Cancer Res; 2010 Jun; 16(11):2927-31. PubMed ID: 20484021
[TBL] [Abstract][Full Text] [Related]
15. CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis.
Tanegashima K; Suzuki K; Nakayama Y; Tsuji K; Shigenaga A; Otaka A; Hara T
FEBS Lett; 2013 Jun; 587(12):1731-5. PubMed ID: 23669361
[TBL] [Abstract][Full Text] [Related]
16. Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis.
Wang L; Wang L; Yang B; Yang Q; Qiao S; Wang Y; Sun Y
Clin Exp Metastasis; 2009; 26(8):1049-54. PubMed ID: 19859817
[TBL] [Abstract][Full Text] [Related]
17. The good and bad faces of the CXCR4 chemokine receptor.
Teixidó J; Martínez-Moreno M; Díaz-Martínez M; Sevilla-Movilla S
Int J Biochem Cell Biol; 2018 Feb; 95():121-131. PubMed ID: 29288743
[TBL] [Abstract][Full Text] [Related]
18. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
19. pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma.
Struckmann K; Mertz K; Steu S; Storz M; Staller P; Krek W; Schraml P; Moch H
J Pathol; 2008 Mar; 214(4):464-71. PubMed ID: 18189328
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma: A potent biomarker predicting lymph node metastasis.
Dayer R; Babashah S; Jamshidi S; Sadeghizadeh M
J Cancer Res Ther; 2018; 14(2):345-350. PubMed ID: 29516917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
